| Wissenschaftl. Titel | A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide and Dexamethasone with and without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma |
| Erkrankung |
Haema:
Multiples Myelom:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (EudraCT) |
erstellt 11.01.2024 Data entry III CCP
geändert 11.01.2024 Data entry III CCP